A clinical trial indicates that using an investigational medical device to close a PFO, or "hole in the heart," may be superior to medical management alone in the prevention of a repeated stroke. Results of the RESPECT trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF)
A clinical trial that compared catheter-based PFO closure using an investigational device found that there was no significant reduction in ischemic and bleeding events compared to standard medical therapy; stroke risk was non-significantly reduced with device therapy. The PC Trial was presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world s premier educational meeting specializing in interventional cardiovascular medicine.
The MGuard Embolic Protection Stent (EPS) (InspireMD) was shown to be significantly superior when compared to standard bare metal and drug eluting stents in achieving complete ST resolution and restoring normal blood flow. According to results from the MASTER trial presented by Gregg W Stone and director of the Cardiovascular Research and Education Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center, at a Late Breaking Trials Sessions at TCT.
Contrary to previous data, STEMI patients with prior open heart surgery, or coronary artery bypass graft surgery (CABG) and receive a coronary stent have similar outcomes to patients without previous CABG, based on study of a large, prospective, regional STEMI network, presented at TCT.
Boston Scientific has received European approval to update the directions for use (DFU) labeling for Promus Element and Promus Element Plus Coronary Stent Systems to include three-month dual anti-platelet therapy (DAPT).
A semi-structured survey suggests that more than 15% of patients suffering from severe symptomatic aortic stenosis eligible for transcatheter aortic valve implantation (TAVI) did not receive the treatment for budget-related reasons in 2011.
A strategy of up-front percutaneous coronary intervention (PCI) for lesions confirmed to be obstructive by fractional flow reserve (FFR) was shown to be cost-effective in terms of quality-adjusted life years when compared to medical therapy alone. Results of the Cost-Effectiveness sub study of the FAME 2 trial were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world s premier educational meeting specializing in interventional cardiovascular medicine.
A study found that second-generation drug-eluting stents are safe and effective in the treatment of left main coronary artery lesions. Results of the ISAR-LEFT MAIN 2 trial were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world s premier educational meeting specializing in interventional cardiovascular medicine.
SAN DIEGO, Oct. 25, 2012 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that St. Jude Medical agreed that previous versions of its PressureWire® products infringed Volcano s 6,976,965 patent (a pressure sensing guide wire patent). Proceedings on damages have not yet been scheduled. In addition, a jury in the federal district court in Delaware has issued a verdict in St. Jude Medical s favor with respect to Volcano s patents at issue in the Company s ongoing patent lawsuit with St. Jude Medical, finding that St. Jude Medical s PressureWire® products do not infringe three of Volcano s patents.
Volcano has announced the global launch of the PrimeWire Prestige Plus pressure guidewire with AcuSense technology, which allows for more precise measurements when distal pressure is monitored for longer periods of time.
Sevilla, Octubre de 2012.- La Sociedad Española de Cardiología (SEC) acaba de presentar en el marco de la XLVIII edición del Congreso de las Enfermedades Cardiovasculares SEC 2012, la realización de un estudio pionero en nuestro país que determinará el riesgo de eventos tromboembólicos y hemorrágicos así como la relación coste-efectividad de los nuevos anticoagulantes administrados a pacientes con fibrilación auricular no valvular (FA).
St. Jude Medical Inc. (STJ) s device to plug openings in the heart after a stroke failed to definitively prevent repeat incidents in patients under age 60 compared with non-surgical drug treatment, two studies found.
Second-generation drug-eluting stents are safe and effective in the treatment of left main coronary artery lesions, according to results of the ISAR-LEFT MAIN 2 trial presented at the TCT congress on 24 October. Data from the study were presented by lead investigator, Julinda Mehilli, director of Catheterization Laboratories at the Medizinische Klinik I, Klinikum der Universitaet Munich, Munich, Germany.
A new analysis of the global RESOLUTE clinical trial has shown that interrupting dual antiplatelet therapy after 30 days following the implantation of a Resolute drug-eluting stent (Medtronic) caused no increase in rates of stent thrombosis at one year. The analysis was presented by Sigmund Silber, director of the Heart Centre at the Isar in Munich, Germany, at TCT.
Stentys has received investigational device exemption (IDE) approval from the FDA to conduct a pivotal clinical trial in the United States which, if successfully completed, will enable the company to apply for marketing approval of the Stentys Self-Apposing stent to treat acute myocardial infarction.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos